The NCI Division of Cancer Prevention funds new research in cancer prevention, detection, screening, interception, and symptom management. We also fund programs to train people for careers in research. Explore current open funding opportunities here and streamline your search by using keyword or type of funding.
Information about the funding opportunity announcements that align with the efforts of the Cancer MoonshotSM can be found here: https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative/funding .
Notice of Funding Opportunities
Title
Announcement Number
Activity Code
Clinical Trials Status
Expiration Date
Program Official
Notice of Special Interest (NOSI): Targeting the Endocannabinoid System for Brain Health and Acute and Chronic Diseases
NOT-DA-22-048
01/08/2026
Sharon Ross, Ph.D., M.P.H.
Notice of Special Interest (NOSI): Mechanisms Driving Obesity and Prostate Cancer Risk
NOT-CA-23-089
09/08/2024
Edward Sauter, M.D., Ph.D.
Assay Validation of High Quality Markers for Clinical Studies in Cancer
PAR-23-313 (UH2/UH3 Clinical Trial Not Allowed)
UH2, UH3
Clinical Trial Not Allowed
10/15/2026
Sudhir Srivastava, Ph.D., M.P.H.
Assay Validation of High Quality Markers for Clinical Studies in Cancer
PAR-23-314 (UH3 Clinical Trials Not Allowed)
UH3
10/15/2026
Sudhir Srivastava, Ph.D., M.P.H.
NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers
PAR-23-286 (K99/R00 - Independent Clinical Trial Not Allowed)
R00, K99
Clinical Trial Not Allowed
10/15/2026
Jessica Faupel-Badger, Ph.D., M.P.H.
NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers
PAR-23-287 (K99/R00 - Independent Clinical Trial Required)
R00, K99
Clinical Trial Required
10/15/2026
Jessica Faupel-Badger, Ph.D., M.P.H.
NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers
PAR-23-288 (K99/R00 - Independent Basic Experimental Studies with Humans Required)
R00, K99
10/15/2026
Jessica Faupel-Badger, Ph.D., M.P.H.
Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research
RFA-CA-24-009 (R33 Clinical Trial Not Allowed)
R33
Clinical Trial Not Allowed
10/02/2024
Guillermo Marquez, Ph.D.
Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research
RFA-CA-24-008 (R61 Clinical Trial Not Allowed)
R61
Clinical Trial Not Allowed
10/02/2024
Guillermo Marquez, Ph.D.
Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research
RFA-CA-24-012 (R01 Clinical Trial Optional)
R01
Clinical Trial Optional
10/02/2024
Guillermo Marquez, Ph.D.